FDA approves 1st plasmid DNA-based immunotherapy in US

The FDA has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the U.S., for adults with recurrent respiratory papillomatosis. The therapy, also known as doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd, was approved Oct. 30, according to an FDA news release. Recurrent respiratory papillomatosis is a rare, chronic disease caused by HPV types […] The post FDA approves 1st plasmid DNA-based immunotherapy in US appeared first on Becker&#...